NazivinÂ® (oxymetazoline) has a vasoconstrictor effect. When applied locally to the inflamed nasal mucosa, it reduces swelling and discharge from the nose. Restores nasal breathing. Elimination of mucosal edema helps restore aeration of the sinuses, middle ear cavity, which prevents the development of bacterial complications (sinusitis, sinusitis, otitis media).
With topical intranasal use at therapeutic concentrations, it does not irritate the mucosa, does not cause hyperemia. With local intranasal use, the drug does not have a systemic effect. The drug begins to act quickly (within a few minutes). The duration of action of Nazivin is up to 12 hours.
treatment of acute respiratory infections accompanied by a runny nose
to restore drainage in case of inflammation of the sinuses, eustachitis, otitis media
to eliminate edema before diagnostic procedures in the nasal passages.
Atrophic rhinitis angle-closure glaucoma hypersensitivity to the components of the drug. Recommended concentrations of the drug intended for different age categories should be adhered to (see methods of use).
In patients taking monoamine oxidase inhibitors and other drugs that increase blood pressure up to 10 days after their use with increased intraocular pressure, during pregnancy and lactation, in severe forms of cardiovascular diseases (hypertension, angina pectoris) with thyrotoxicosis and diabetes mellitus.
Use during pregnancy and lactation
When used during pregnancy or breastfeeding, the recommended dosage should not be exceeded. The drug should be used only after a thorough assessment of the risk-benefit ratio for the mother and the fetus.
1 ml of the preparation contains:
Nazivin 0.01% – Oxymethazoline hydrochloride 0.1 mg
Nazivin 0.025% – Oxymethazoline hydrochloride 0.25 mg
Nazivin 0.05% – Oxymethazole mg
benzalkonium chloride 50% solution,
disodium edetate dihydrate,
sodium dihydrogen phosphate dihydrate,
sodium hydrogen phosphate dihydrate,
sodium hydroxide 1 M solution,
Dosage and administration
nasivinÂ® 0.01%, 0.025% and 0.05% drops are intended for use in the nose.
Adults and children over 6 years of age: use NazivinÂ® drops of 0.05%, 1 to 2 drops in each nasal passage 2 to 3 times a day.
Children from 1 year to 6 years: apply NazivinÂ® drops of 0.025%, 1 to 2 drops in each nasal passage 2 to 3 times a day.
Children under 1 year of age: Children under the age of 4 weeks are prescribed 1 drop of NazivinÂ® 0.01% in each nasal passage 2-3 times a day. From the 5th week of life and up to 1 year – 1 – 2 drops in each nasal passage 2 – 3 times a day. To ensure the dosage accuracy, the NazivinÂ® bottle of 0.01% drops has a graduated pipette with marks of the number of drops. For example, if 1 drop is assigned, then the pipette should be filled with a solution to the mark of 1. The following procedure has also been proven effective: depending on the age, 1 – 2 drops of a 0.01% solution are applied to cotton and wipe the nasal passages.
NazivinÂ® 0.01%, 0.025% and 0.05% drops should be used 3-5 days. Doses higher than recommended can only be used under medical supervision.
Sometimes: burning or dry nasal membranes, sneezing.
In rare cases: after the effect of the use of NazivinÂ® passes, a strong feeling of nasal congestion (reactive hyperemia). Repeated overdose with local nasal use sometimes leads to systemic sympathomimetic effects such as increased heart rate (tachycardia) and increased blood pressure.
In very rare cases, anxiety, insomnia, fatigue, headaches, and nausea have been observed.
Prolonged continuous use of vasoconstrictor drugs can lead to tachyphylaxis, atrophy of the nasal mucosa and recurrent swelling of the nasal mucosa (drug rhinitis).
Symptoms: with significant overdose or ingestion, pupil constriction, nausea, vomiting, cyanosis, fever, tachycardia, arrhythmia, collapse, cardiac arrest, hypertension, hypertension may occur. In addition, disorders of the psyche can be observed, as well as depression of the CNS function, accompanied by drowsiness, decreased body temperature, bradycardia, arterial hypotension, respiratory arrest and possible development of coma.
Treatment: gastric lavage, activated charcoal intake.
At a temperature not exceeding 25 ° C.
Merck KGaA, Russia